India–UK FTA, effective July 15, 2026, introduces mutual regulatory recognition for medical devices. Additionally, it removes tariffs on Indian exports, such as surgical instruments, diagnostic equipment, ECG machines, and X-ray systems. This means Indian manufacturers will face lower compliance costs and gain easier access to the UK’s USD 32 billion medical devices market, which is projected to more than double by 2035. The agreement also requires both countries to give “positive consideration” to accepting each other’s technical regulations and product testing as equivalent. Moreover, reasons for rejection have to be provided promptly. For India, this is seen as a landmark step that strengthens credibility of its regulatory system and opens up NHS procurement opportunities. Furthermore, it serves as a template for future trade deals with the EU and other regions, thereby positioning India as a growing global medtech hub.
India–UK FTA enhancing medical device opportunity in UK
India–UK Free Trade Agreement (FTA) establishes mutual regulatory recognition for medical devices. Additionally, it removes tariffs on Indian exports, such as surgical instruments, diagnostic equipment, and imaging systems. This will give Indian manufacturers easier access to the UK’s USD 32 billion market. This is seen as a landmark step that could serve as a model for future EU agreements. However, industry leaders warn of risks from third-country rerouting. Nations, such as China or EU states, could channel products through the UK to exploit duty-free access in India. They are urging strict rules-of-origin safeguards and stronger customs checks to prevent misuse. Furthermore, they emphasised that without such measures, India’s “Make in India” push could be undermined despite the India–UK FTA’s potential to boost exports and global credibility.
Key highlights of the India–UK FTA for medical devices industry
- Regulatory recognition: India and the UK will give positive consideration to accepting each other’s technical regulations and product testing as equivalent. If rejected, reasons must be provided within a reasonable timeframe.
- Tariff elimination: Zero-duty access for Indian medical devices, such as surgical instruments, diagnostic equipment, ECG machines, and X-ray systems. Strengthens competitiveness of Indian manufacturers in the UK market.
- Market opportunity: UK medical devices market is valued at USD 32 billion in 2024, which is projected to reach USD 69 billion by 2035. NHS procurement system could now be more accessible to Indian firms, thereby reducing compliance costs.
- Strategic impact: Seen as a “proof-of-concept” for similar agreements with the EU and other regions, thereby potentially positioning India as a top-five global MedTech hub by 2030.
Industry concerns
- Third-country rerouting: Many Indian manufacturers worry that countries, such as China or EU members, could route their products through the UK to gain duty-free access to India. This would allow non-FTA nations to exploit the agreement without genuinely contributing to bilateral trade. Past experiences with Singapore and the Netherlands show how rerouting can distort import patterns despite limited domestic manufacturing. Without strict checks, this loophole could undermine India’s “Make in India” initiative and weaken local industry competitiveness.
- Rules-of-origin enforcement: Industry bodies stress the need for strong rules-of-origin safeguards to ensure only genuine UK-origin products benefit from the FTA. They recommend factory inspections, tighter certification monitoring, and customs vigilance to prevent misuse. Weak enforcement could lead to a surge in imports that are merely repackaged or re-routed through the UK. Effective safeguards are seen as critical to protect India’s domestic manufacturing base and ensure fair competition.
- Regulatory imbalance: Indian exporters must clear costly and time-consuming approvals, such as UK MHRA or EU CE certifications, to access the UK market. In contrast, UK manufacturers can enter India through CDSCO approvals, which are faster and less expensive. This imbalance creates a competitive disadvantage for Indian firms despite tariff-free access. Industry leaders argue that India should introduce stricter inspection requirements for imports to level the playing field.
- Import dependency risk: India’s medical device imports already far exceed exports. If rerouting and regulatory imbalances are not addressed, the FTA could unintentionally worsen this dependency. Increased imports without corresponding export growth would strain India’s trade balance in the medtech sector. Industry stakeholders emphasize that the agreement must be implemented carefully to strengthen domestic manufacturing rather than deepen reliance on foreign suppliers.
India–UK FTA implications for the Indian medical device industry
Benefits
- Boost to exports: Indian medical device manufacturers gain tariff-free access to the UK market, thereby reducing costs and improving competitiveness. This opens opportunities in the UK’s NHS procurement system, which is highly regulated and previously difficult to penetrate. The agreement strengthens India’s credibility as a reliable supplier in global medtech trade.
- Strengthened regulatory standing: Mutual recognition of technical regulations enhances the global acceptance of India’s regulatory framework. This reduces duplication of testing and certification, thereby saving time and resources for exporters. Moreover, it also positions India as a trusted partner for future trade agreements with the EU and other regions.
- Pathway to global expansion: The India–UK FTA acts as a “proof-of-concept” for similar deals with Europe and other markets. By demonstrating successful regulatory alignment with the UK, India can negotiate broader recognition agreements. This supports India’s ambition to become a top-five global medtech hub by 2030.
- Domestic industry growth: Lower barriers to export encourage Indian manufacturers to scale production and invest in innovation. The agreement incentivizes companies to upgrade quality systems to meet international standards. Over time, this could reduce India’s reliance on imports and strengthen its domestic medtech ecosystem.
Risks:
- Without strict enforcement, rerouting could undermine “Make in India” gains.
- Regulatory imbalance may disadvantage Indian exporters.
- Import dependency could worsen if safeguards are weak.
Conclusions
Therefore, the India–UK FTA marks a significant milestone for India’s medical device sector by enabling tariff-free exports and mutual regulatory recognition. Hence, it will lower compliance costs and open doors to the UK’s expanding healthcare market. It strengthens India’s global credibility, provides a pathway to NHS procurement, and sets a precedent for similar agreements with the EU and other regions. However, the industry stakeholders highlight the need for vigilance against rerouting and regulatory imbalances. Notably, the agreement overall positions India to accelerate its medtech growth, enhance domestic manufacturing, and move closer to its ambition of becoming a top-five global medical device hub by 2030. Email at [email protected] or call/Whatsapp on 9996859227 for any regulatory queries.
